Patents by Inventor Junken Aoki
Junken Aoki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230310376Abstract: A prophylactic and/or therapeutic agent for idiopathic pulmonary fibrosis is disclosed. The prophylactic and/or therapeutic agent for idiopathic interstitial pneumonia (IPF or the like) contains a compound having an LPA3 agonistic activity or a salt thereof.Type: ApplicationFiled: August 25, 2021Publication date: October 5, 2023Applicants: ONO PHARMACEUTICAL CO., LTD.,, TOHOKU UNIVERSITYInventors: Junken AOKI, Kuniyuki KANO, Yasuaki HASHIMOTO, Michiaki KADODE, Yuji KAWAHARA
-
Publication number: 20230108750Abstract: It is an object of the present invention to identify a novel analog of carbacyclic phosphatidic acid that is a cyclic phosphatidic acid derivative, and to clarify the physiological activity thereof. According to the present invention, a compound represented by the following formula (1) is provided: wherein R represents a linear or branched alkyl group containing 1 to 30 carbon atoms, a linear or branched alkenyl group containing 2 to 30 carbon atoms, or a linear or branched alkynyl group containing 2 to 30 carbon atoms, and these groups may optionally comprise a cycloalkane ring or an aromatic ring; and M represents a hydrogen atom or a counter cation.Type: ApplicationFiled: November 20, 2020Publication date: April 6, 2023Applicant: OCHANOMIZU UNIVERSITYInventors: Kimiko MUROFUSHI, Mari GOTOH, Keiko FUKASAWA, Junken AOKI
-
Publication number: 20210318305Abstract: An object of the present invention is to provide a method and a kit that can accurately measure autoantibody activity against a TSH receptor in a short time without pretreating a blood sample (blood specimen). The autoantibody activity against a TSH receptor in a blood sample can be measured by using a kit for measurement of autoantibody activity against a TSH receptor in a mammal cell, comprising a mammal cell expressing both a cAMP biosensor and the TSH receptor, and a substrate capable of visualizing and/or quantifying the cAMP biosensor as constituents, and performing a method comprising the steps of: (a) incubating a mammal cell expressing both a cAMP biosensor and the TSH receptor in the presence of a blood sample collected from a test subject; (b) measuring an activation level of the cAMP biosensor after the step (a); and (c) comparing the activation level measured in the step (b) with an activation level in a control to calculate the autoantibody activity.Type: ApplicationFiled: September 2, 2019Publication date: October 14, 2021Inventors: Atsushi Kawasaki, Motoki Hoshina, Junken Aoki, Kouki Kawakami, Asuka Inoue
-
Patent number: 10189843Abstract: The present invention provides a compound of formula (1), wherein R1, R2, R3, R4a, R4b, R5a and R5b are as defined in the description, which has an autotaxin inhibitory activity, a pharmaceutical composition comprising the compound as an active ingredient, and a method of prevention or treatment of a disease involving autotaxin, which is characterized by administering the compound.Type: GrantFiled: February 26, 2015Date of Patent: January 29, 2019Assignees: THE UNIVERSITY OF TOKYO, TOHOKU UNIVERSITY, SHIONOGI & CO., LTD.Inventors: Tetsuo Nagano, Takayoshi Okabe, Hirotatsu Kojima, Mitsuyasu Kawaguchi, Osamu Nureki, Ryuichiro Ishitani, Hiroshi Nishimasu, Junken Aoki, Chiaki Fujikoshi, Manabu Katou, Masahide Odan, Nobuyuki Tanaka, Yusuke Tateno, Junji Yamane
-
Patent number: 10183949Abstract: A compound according to any one of formula (Ia) to (Ic), or its pharmaceutically acceptable salt: wherein R1, R2, R3, R4a, R4c, R5 are as defined in the description.Type: GrantFiled: February 24, 2017Date of Patent: January 22, 2019Assignees: THE UNIVERSITY OF TOKYO, TOHOKU UNIVERSITY, SHIONOGI & CO., LTD.Inventors: Tetsuo Nagano, Takayoshi Okabe, Hirotatsu Kojima, Mitsuyasu Kawaguchi, Osamu Nureki, Ryuichiro Ishitani, Hiroshi Nishimasu, Junken Aoki, Nobuyuki Tanaka, Yasuhiko Kanda, Yoshiyuki Kioi, Yusuke Tateno, Shiro Kida, Junji Yamane
-
Patent number: 9856278Abstract: An object of the present invention is to provide a lysophosphatidylserine derivative or a salt thereof. The present invention provides a lysophosphatidylserine derivative or a salt thereof, or a pharmaceutical composition or a lysophosphatidylserine receptor function modulator comprising said compound or a salt thereof.Type: GrantFiled: July 3, 2015Date of Patent: January 2, 2018Assignee: THE UNIVERSITY OF TOKYOInventors: Tomohiko Ohwada, Sho Nakamura, Sejin Jung, Yuko Otani, Misa Sayama, Junken Aoki
-
Publication number: 20170210767Abstract: An object of the present invention is to provide a lysophosphatidylserine derivative or a salt thereof. The present invention provides a lysophosphatidylserine derivative or a salt thereof, or a pharmaceutical composition or a lysophosphatidylserine receptor function modulator comprising said compound or a salt thereof.Type: ApplicationFiled: July 3, 2015Publication date: July 27, 2017Applicant: THE UNIVERSITY OF TOKYOInventors: Tomohiko OHWADA, Sho NAKAMURA, Sejin JUNG, Yuko OTANI, Misa SAYAMA, Junken AOKI
-
Publication number: 20170158704Abstract: A compound according to any one of formula (Ia) to (Ic), or its pharmaceutically acceptable salt: wherein R1, R2, R3, R4a, R4c, R5 are as defined in the description.Type: ApplicationFiled: February 24, 2017Publication date: June 8, 2017Applicants: The University of Tokyo, TOHOKU UNIVERSITY, Shionogi & Co., Ltd.Inventors: Tetsuo NAGANO, Takayoshi OKABE, Hirotatsu KOJIMA, Mitsuyasu KAWAGUCHI, Osamu NUREKI, Ryuichiro ISHITANI, Hiroshi NISHIMASU, Junken AOKI, Nobuyuki TANAKA, Yasuhiko KANDA, Yoshiyuki KIOI, Yusuke TATENO, Shiro KIDA, Junji YAMANE
-
Publication number: 20160376278Abstract: The present invention provides a compound of formula (1), wherein R1, R2, R3, R4a, R4b, R5a and R5b are as defined in the description, which has an autotaxin inhibitory activity, a pharmaceutical composition comprising the compound as an active ingredient, and a method of prevention or treatment of a disease involving autotaxin, which is characterized by administering the compound.Type: ApplicationFiled: February 26, 2015Publication date: December 29, 2016Applicants: The University of Tokyo, TOHOKU UNIVERSITY, Shionogi & Co., Ltd.Inventors: Tetsuo NAGANO, Takayoshi OKABE, Hirotatsu KOJIMA, Mitsuyasu KAWAGUCHI, Osamu NUREKI, Ryuichiro ISHITANI, Hiroshi NISHIMASU, Junken AOKI, Chiaki FUJIKOSHI, Manabu KATOU, Masahide ODAN, Nobuyuki TANAKA, Yusuke TATENO, Junji YAMANE
-
Patent number: 9469665Abstract: The object of the present invention is to provide a compound having a lysophosphatidylserine receptor function modulation activity or a salt thereof. A compound having a lysophosphatidylserine receptor function modulation activity or a salt thereof, or a pharmaceutical composition or a lysophosphatidylserine receptor function moderator containing such compound or salt is provided by the present invention.Type: GrantFiled: January 30, 2014Date of Patent: October 18, 2016Assignees: THE UNIVERSITY OF TOKYO, TOHOKU UNIVERSITYInventors: Tomohiko Ohwada, Yuko Otani, Masaya Ikubo, Sho Nakamura, Sejin Jung, Junken Aoki, Kumiko Makide, Asuka Inoue
-
Publication number: 20160002247Abstract: A compound of formula (I) wherein variables are as defined herein having an autotaxin inhibitory effect and a pharmaceutical composition comprising the same.Type: ApplicationFiled: February 27, 2014Publication date: January 7, 2016Applicants: THE UNIVERSITY OF TOKYO, TOHOKU UNIVERSITY, Shionogi & Co., Ltd.Inventors: Tetsuo NAGANO, Takayoshi OKABE, Hirotatsu KOJIMA, Mitsuyasu KAWAGUCHI, Osamu NUREKI, Ryuichiro ISHITANI, Hiroshi NISHIMASU, Junken AOKI, Nobuyuki TANAKA, Chiaki FUJIKOSHI, Yusuke TATENO, Toshihiro WADA
-
Publication number: 20150361119Abstract: The object of the present invention is to provide a compound having a lysophosphatidylserine receptor function modulation activity or a salt thereof. A compound having a lysophosphatidylserine receptor function modulation activity or a salt thereof, or a pharmaceutical composition or a lysophosphatidylserine receptor function moderator containing such compound or salt is provided by the present invention.Type: ApplicationFiled: January 30, 2014Publication date: December 17, 2015Applicants: TOHOKU UNIVERSITY, THE UNIVERSITY OF TOKYOInventors: Tomohiko OHWADA, Yuko OTANI, Masaya IKUBO, Sho NAKAMURA, Sejin JUNG, Junken AOKI, Kumiko MAKIDE, Asuka INOUE
-
Publication number: 20100120064Abstract: A screening method is provided for antibody specifically recognizing naturally-occurring form of human autotaxin in a state in which it is present in the body without being denatured, comprising the steps of: binding a binding factor capable of capturing a candidate antibody of the antibody to a solid phase; binding the candidate antibody of the antibody to the binding factor; allowing naturally-occurring form of human autotaxin to react on a system in which the candidate antibody has reacted; and selecting an antibody that specifically recognizes the naturally-occurring form of human autotaxin by using as an indicator thereof the binding strength of the naturally-occurring form of human autotaxin to the antibody.Type: ApplicationFiled: August 2, 2007Publication date: May 13, 2010Applicants: The University of Tokyo, TOSOH CORPORATIONInventors: Junken Aoki, Hiroyuki Arai, Yutaka Yatomi, Hitoshi Ikeda, Kazuhiro Nakamura, Koji Igarashi, Kazufumi Ide
-
Publication number: 20070202520Abstract: A novel phospholipase A1 (PLA1) having a substrate specificity to phosphatidic acid (PA); a peptide or a polypeptide originating in the above novel PLA1; a polynucleotide encoding the peptide or polypeptide originating in the novel PLA1; a process for producing the peptide or polypeptide originating in the novel PLA1; an antibody against the peptide or polypeptide originating in the novel PLA1; a method of identifying an inhibitor, an antagonist or an activator of the novel PLA1 by using the same; compounds identified by the above method; and medicinal compositions and diagnostic methods by using the same.Type: ApplicationFiled: January 11, 2007Publication date: August 30, 2007Inventors: Junken Aoki, Hiroyuki Arai, Keizo Inoue
-
Publication number: 20040253221Abstract: A novel phospholipase A1 (PLA1) having a substrate specificity for phosphatidic acid (PA): a peptide or a polypeptide originating in the novel PLA1: a polynucleotide encoding the peptide or the polypeptide originating in the novel PLA1: a process for producing the peptide or the polypeptide originating in the novel PLA1: an antibody against the peptide or the polypeptide originating in the novel PLA1: a method of identifying an inhibitor, an antagonist or a potentiator for the novel PLA1 by using the same: a compound identified by this method: and medicinal compositions and a diagnostic method with the use of the same.Type: ApplicationFiled: August 18, 2003Publication date: December 16, 2004Inventors: Hiroyuki Arai, Junken Aoki
-
Publication number: 20040053893Abstract: The present invention provides a lysophospholipid of the formula (I) 1Type: ApplicationFiled: June 27, 2003Publication date: March 18, 2004Inventors: Tatsuya Kishimoto, Yasuji Soda, Yoshiko Matsuyama, Hiroyuki Arai, Junken Aoki